PTK2 and familial pancreatic carcinoma: Whilst anti-fibrotic therapies, such as FAK inhibitors, can offer promising new clinical opportunities for pancreatic cancer management, it is not obvious how to combine them with other treatments to maximise therapeutic efficacy.